China Health Group Ltd

China Health Group Ltd has a market capitalization of HKD 776.8 million, with a market price of HKD 0.56 per share. The company has 1.39 billion shares outstanding, with no dilution observed between basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company reported a last actual EPS of HKD 0.40 and a last actual revenue of HKD 2.87 billion. While these figures provide a snapshot of profitability, they must be compared to industry benchmarks to assess performance. The industry_config for the Medical Equipment, Supplies & Distribution sector emphasizes metrics such as EBITDA margins, ROIC, and revenue growth. Without access to these metrics for the cohort median, a direct comparison is not possible.

The company's revenue is not segmented by geographic region or business line in the available data, making it difficult to assess exposure to specific markets or product lines. This lack of segmentation limits the ability to evaluate diversification and potential concentration risks.

The company's growth trajectory is not explicitly outlined in the available data. Analysts have reported last actual revenue and EPS figures, but forward-looking guidance or projections are not provided. Without a clear outlook for the current or next fiscal year, it is challenging to assess the company's growth potential.

Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. Additionally, the company has a low dilution risk, as no dilution is observed between basic and diluted shares. However, the absence of going-concern language in source documents raises concerns about the company's financial health and operational continuity.

Recent events and filings are not detailed in the available data, limiting the ability to assess any material developments that may impact the company's operations or financial performance.

Revenue HK$38.9M, −35,0% YoY; Operating income −60,0% YoY.

• ▍Revenue HK$38.9M, −35,0% YoY
• ▍Operating income −60,0% YoY
• ▍Net income −68,7% YoY
• ▍Free cash flow −71,1% YoY
• ▍Net margin -174.1%

Revenue HK$59.9M, −21,6% YoY; Operating income −26,4% YoY.

• ▍Revenue HK$59.9M, −21,6% YoY
• ▍Operating income −26,4% YoY
• ▍Net income +4,4% YoY
• ▍Free cash flow −4,9% YoY
• ▍Net margin -67.1%

Revenue HK$76.4M, −28,6% YoY; Operating income −294,4% YoY.

• ▍Revenue HK$76.4M, −28,6% YoY
• ▍Operating income −294,4% YoY
• ▍Net income −244,5% YoY
• ▍Free cash flow −525,6% YoY
• ▍Net margin -55.0%

Revenue HK$107.0M, +21,8% YoY; Operating income −67,1% YoY.

• ▍Revenue HK$107.0M, +21,8% YoY
• ▍Operating income −67,1% YoY
• ▍Net income −57,6% YoY
• ▍Free cash flow −21,8% YoY
• ▍Net margin -11.4%

Revenue HK$87.9M; Operating income -HK$5.0M.

• ▍Revenue HK$87.9M
• ▍Operating income -HK$5.0M
• ▍Net margin -8.8%